BACKGROUND: Two methods of paralysis are available for rapid sequence intubation (RSI) in the emergency department (ED): depolarizing agents such as succinylcholine, and non-depolarizing drugs such as rocuronium. Rocuronium is a useful alternative when succinylcholine is contraindicated. Contraindications to succinylcholine include allergy, history of malignant hyperthermia, denervation syndromes, and patients who are 24-48 h post burn or crush injury. Non-depolarizing drugs have the advantage of causing less pain due to post-paralysis myalgias. CLINICAL QUESTION: Can rocuronium replace succinylcholine as the paralytic of choice for RSI in the ED? EVIDENCE REVIEW: Four relevant studies were selected from an evidence search and a structured review performed. RESULTS: For the outcomes of clinically acceptable intubation conditions and time to onset, the two agents were not statistically significantly different. Succinylcholine seems to produce conditions that have higher satisfaction scores. CONCLUSION: Succinylcholine remains the drug of choice for ED RSI unless there is a contraindication to its usage.
BACKGROUND: Two methods of paralysis are available for rapid sequence intubation (RSI) in the emergency department (ED): depolarizing agents such as succinylcholine, and non-depolarizing drugs such as rocuronium. Rocuronium is a useful alternative when succinylcholine is contraindicated. Contraindications to succinylcholine include allergy, history of malignant hyperthermia, denervation syndromes, and patients who are 24-48 h post burn or crush injury. Non-depolarizing drugs have the advantage of causing less pain due to post-paralysis myalgias. CLINICAL QUESTION: Can rocuronium replace succinylcholine as the paralytic of choice for RSI in the ED? EVIDENCE REVIEW: Four relevant studies were selected from an evidence search and a structured review performed. RESULTS: For the outcomes of clinically acceptable intubation conditions and time to onset, the two agents were not statistically significantly different. Succinylcholine seems to produce conditions that have higher satisfaction scores. CONCLUSION:Succinylcholine remains the drug of choice for ED RSI unless there is a contraindication to its usage.
Authors: Mi Ja Yun; Yoon Hee Kim; Young Kwon Go; Ji Eun Shin; Choon Gun Ryu; Won Kim; Nam Jong Paik; Moon Ku Han; Sang Hwan Do; Woo Suk Jung Journal: Yonsei Med J Date: 2010-07 Impact factor: 2.759
Authors: Chittaranjan Andrade; N Shah; P Tharyan; M S Reddy; M Thirunavukarasu; R A Kallivayalil; R Nagpal; N K Bohra; A Sharma; E Mohandas Journal: Indian J Psychiatry Date: 2012-04 Impact factor: 1.759
Authors: Stephan C Marsch; Luzius Steiner; Evelyne Bucher; Hans Pargger; Martin Schumann; Timothy Aebi; Patrick R Hunziker; Martin Siegemund Journal: Crit Care Date: 2011-08-16 Impact factor: 9.097
Authors: Heinz Jungbluth; Nicol C Voermans; Luuk R van den Bersselaar; Marc M J Snoeck; Madelief Gubbels; Sheila Riazi; Erik-Jan Kamsteeg Journal: Pract Neurol Date: 2020-10-27
Authors: Brian C Geyer; Katherine E Larrimore; Jacquelyn Kilbourne; Latha Kannan; Tsafrir S Mor Journal: PLoS One Date: 2013-03-11 Impact factor: 3.240
Authors: C Frerk; V S Mitchell; A F McNarry; C Mendonca; R Bhagrath; A Patel; E P O'Sullivan; N M Woodall; I Ahmad Journal: Br J Anaesth Date: 2015-11-10 Impact factor: 9.166